Funding for Medical Research
and Clinical Trials
and Clinical Trials
Funding Details for Cancer
Use the contact information shown for the organization to apply for the funding.
Please notify CenTrial of any offer is incorrect or has expired.
Please notify CenTrial of any offer is incorrect or has expired.
Leukemia & Lymphoma
Leukemia & Lymphoma Society
Type of Organization: Foundation
Email Address: researchprograms@lls.org
Funds Available for Clinical Trials: ✗ Research: ✔
The program welcomes applications worldwide from appropriate academic institutions and investigators of any nationality. Degree Applicants must hold a PhD, MD, DVM, or equivalent degree. Leadership and Staffing The Principal Investigator (PI):
• MUST be a person (companies or institutions are not eligible)
• MUST be an independent investigator, defined as a scientist who has dedicated laboratory space, directly hires, and supervises laboratory personnel (technicians, graduate students, postdocs, and staff scientists), and makes all decisions concerning research activities and use of the grant funds
• MUST be an established investigator, defined as a researcher with more than 3 years in an independent faculty appointment
• May only submit one application per application cycle per grant program provided the aims differ
• CAN serve as a Collaborator on other applications provided the aims differ
• If the applicant can demonstrate a significant track record in malignant hematology and/or blood cancer research, a Co-PI may strengthen the proposal but is not required
• If the applicant has scientific achievements and significant expertise in another scientific area and no track record in blood cancer research, he or she MUST have a Co-Principal Investigator who has the required significant track record in hematology and/or blood cancer research Not eligible to apply for a grant in this program:
• Predoctoral scientists or postdoctoral fellow A Co-Principal Investigator (Co-PI):
• MUST be a person (companies or institutions are not eligible)
• MUST be an independent investigator with an independent appointment
• If the PI has the necessary track record in blood cancer research, a Co-PI may strengthen the proposal but is not required
• If the PI has no expertise or proven track record in any of the blood cancers, an expert Co-PI is REQUIRED
• May only submit one application per application cycle per grant program provided the aims differ
• CAN serve as a Collaborator on other applications provided the aims differ
• MUST be designated at the LOI phase detailing the nature and extent of the scientific interaction
• At least one research aim of the proposal fully depends on their expertise, typically performed in their laboratory and/or facility
Scientific Staff/Collaborators/Other Key Personnel • MUST be a person (companies or institutions are not eligible) • May strengthen the work proposed but is not required • May provide expert insight, guidance, or feedback on research progress • May be included on different projects or programs provided the aims differ The Application will require one Principal Investigator who is responsible for the preparation and submission of the proposal including budget, the conduct of the research programs, and adherence with all stipulations made by LLS in this document, the Policies & Procedures document, and in the Funding Agreement, if funded. Relevance The proposed research should be clinically directed or clinically translatable in hematologic malignancies that is intended to develop innovative approaches to treatment, diagnosis, or prevention.
Other info: The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness.
We are looking for applications that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative and with a clear plan for the eventual clinical translation of the studies proposed and the results expected.
Applications for year 2024-2025 opens in Fall.
Leukemia & Lymphoma Society
Type of Organization: Foundation
Email Address: researchprograms@lls.org
Funds Available for Clinical Trials: ✗ Research: ✔
Funding Details
Requirements: CitizenshipThe program welcomes applications worldwide from appropriate academic institutions and investigators of any nationality. Degree Applicants must hold a PhD, MD, DVM, or equivalent degree. Leadership and Staffing The Principal Investigator (PI):
• MUST be a person (companies or institutions are not eligible)
• MUST be an independent investigator, defined as a scientist who has dedicated laboratory space, directly hires, and supervises laboratory personnel (technicians, graduate students, postdocs, and staff scientists), and makes all decisions concerning research activities and use of the grant funds
• MUST be an established investigator, defined as a researcher with more than 3 years in an independent faculty appointment
• May only submit one application per application cycle per grant program provided the aims differ
• CAN serve as a Collaborator on other applications provided the aims differ
• If the applicant can demonstrate a significant track record in malignant hematology and/or blood cancer research, a Co-PI may strengthen the proposal but is not required
• If the applicant has scientific achievements and significant expertise in another scientific area and no track record in blood cancer research, he or she MUST have a Co-Principal Investigator who has the required significant track record in hematology and/or blood cancer research Not eligible to apply for a grant in this program:
• Predoctoral scientists or postdoctoral fellow A Co-Principal Investigator (Co-PI):
• MUST be a person (companies or institutions are not eligible)
• MUST be an independent investigator with an independent appointment
• If the PI has the necessary track record in blood cancer research, a Co-PI may strengthen the proposal but is not required
• If the PI has no expertise or proven track record in any of the blood cancers, an expert Co-PI is REQUIRED
• May only submit one application per application cycle per grant program provided the aims differ
• CAN serve as a Collaborator on other applications provided the aims differ
• MUST be designated at the LOI phase detailing the nature and extent of the scientific interaction
• At least one research aim of the proposal fully depends on their expertise, typically performed in their laboratory and/or facility
Scientific Staff/Collaborators/Other Key Personnel • MUST be a person (companies or institutions are not eligible) • May strengthen the work proposed but is not required • May provide expert insight, guidance, or feedback on research progress • May be included on different projects or programs provided the aims differ The Application will require one Principal Investigator who is responsible for the preparation and submission of the proposal including budget, the conduct of the research programs, and adherence with all stipulations made by LLS in this document, the Policies & Procedures document, and in the Funding Agreement, if funded. Relevance The proposed research should be clinically directed or clinically translatable in hematologic malignancies that is intended to develop innovative approaches to treatment, diagnosis, or prevention.
Other info: The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness.
We are looking for applications that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative and with a clear plan for the eventual clinical translation of the studies proposed and the results expected.
Applications for year 2024-2025 opens in Fall.